In future work, we plan to screen the full set of FDA-approved drugs and other bioactive compounds in our high throughput tau/p-Tau imaging assay with the objective of creating new chemical tools for the tauopathy field and potential leads for novel therapeutic development. This evidence concerns the gene MAPT and tauopathy.